Amber Therapeutics Secures $132 Million in Series B Funding to Advance Groundbreaking Neuromodulation Therapies

Alterome Therapeutics, Inc. is thrilled to announce the successful completion of a $132 million funding round, a significant milestone that will accelerate the development of our groundbreaking neuromodulation therapies. Founded in 2021, Amber Therapeutics has made it our mission to address the substantial gaps in clinical care through innovative treatment solutions. Our dynamic and multidisciplinary team, equipped with extensive medical device expertise, is driven by a commitment to transformational innovation. The funding secured will primarily focus on the advancement of our flagship product, Amber UI, which targets mixed urinary incontinence—a condition that affects millions of women globally. With these funds, we aim to enhance our clinical trials, further research, and expedite the regulatory approval process for Amber UI, thereby bringing much-needed relief and improved quality of life to women experiencing this condition. This significant investment underscores the confidence that our investors have in our vision and our team’s ability to execute on it. As we continue to forge ahead, we remain dedicated to pioneering therapies that not only address unmet clinical needs but also set new standards in patient care. We are excited about the next steps in our journey and are committed to delivering solutions that will transform the landscape of neuromodulation therapies.